1,080 material Form 8-K filings that 839 companies we cover made with the SEC in May 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On May 16, 2025, a U.S. District Court in Delaware ruled in Acadia's favor on both infringement and validity in its '721 formulation patent case over Nuplazid (pimavanserin) against Aurobindo and MSN. The same week, Acadia agreed to a 12-year, two-month lease for about 52,771 square feet in Princeton, New Jersey, and will end its current 502 Carnegie Center lease after the new lease begins.
Court ruling date: May 16, 2025, in the U.S. District Court for the District of Delaware, covering both infringement and validity arguments
Defendants in the patent case: Aurobindo Pharma Limited and its affiliate, and MSN Laboratories Private Ltd. and its affiliate
210 Lease: about 52,771 square feet, term of 12 years and 2 months, commencing no later than January 1, 2026, with first-year payment of $1,899,756
Maximum landlord contribution of $5,277,100 for improvements, with a possible $2,638,550 supplemental contribution repayable with 8.00% interest
Keysight reported second-quarter fiscal 2025 revenue of $1.31 billion, up from $1.22 billion a year earlier, and non-GAAP earnings of $1.70 per share, up from $1.41. The company said revenue and EPS were above the high end of its guidance and raised its full-year growth expectations to the midpoint of its long-term 5-7% target. Separately, director Robert A. Rango retired from the board effective May 15, 2025, for personal reasons.
Q2 revenue was $1.31 billion versus $1.22 billion in Q2 2024; GAAP diluted EPS was $1.49 versus $0.72.
Non-GAAP diluted EPS was $1.70 versus $1.41 a year earlier; free cash flow was $457 million versus $74 million.
Third-quarter fiscal 2025 revenue is expected at $1.305 billion to $1.325 billion, with non-GAAP EPS of $1.63 to $1.69.
Director Robert A. Rango retired from the board effective May 15, 2025, for personal reasons, not due to a disagreement with the company.
ANI Pharmaceuticals filed an investor presentation for the H.C. Wainwright BioConnect conference on May 20, 2025, where CEO Nikhil Lalwani is scheduled to present. The deck restates the revised full-year 2025 guidance issued May 9, 2025, which raised net revenue to $768-793 million from $756-776 million and adjusted EBITDA to $195-205 million from $190-200 million, and describes this as the second guidance raise this year.
Full-year 2025 net revenue guidance is $768-793 million, up from $756-776 million; the deck calls this the second guidance raise in 2025.
Adjusted non-GAAP diluted EPS guidance is $6.27-6.62, up from $6.12-6.49.
Q1 2025 total revenue was $197 million, up 43% year over year; Q1 adjusted non-GAAP EBITDA was $51 million, up 35%.
CEO Nikhil Lalwani will present on May 20, 2025 at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.